Stratagene California

Stratagene California was an American biotechnology company established and incorporated in California in 1984. Based in La Jolla, it operated in the life-science research and diagnostics market, supplying technologies and products used in molecular biology, cellular analysis, cloning, cytogenomics, DNA methylation, DNA sizing and quantification, and food testing. Its business was oriented toward specialized laboratory applications rather than consumer healthcare, serving researchers, diagnostic developers, and other professional users. The company’s development reflected the expansion of commercial biotechnology tools during the 1980s and 1990s. Stratagene built a position around enabling technologies for analyzing and manipulating biological material, including tools relevant to DNA research and laboratory workflows. Its activities placed it within a competitive biotechnology-tools sector in which intellectual property, assay performance, reproducibility, and integration into laboratory procedures were central commercial considerations. Contemporary reporting also associated the company with entrepreneurial recognition, intellectual-property disputes, strategic expansion, and efforts to broaden its product and technology base. Stratagene later expanded beyond its original research-tool focus through corporate development activity. In 2004, it acquired Hycor and was reported to have gone public, indicating an effort to broaden its platform and commercial reach. The company also pursued technologies connected with molecular diagnostics and related applications. Its business included work touching food testing and other forms of biological detection, although the available reference material does not provide a complete catalog of branded products or revenue by product category. In 2007, Agilent Technologies acquired Stratagene for a reported price of approximately $250 million. The transaction ended Stratagene’s independence as a standalone biotechnology company. Agilent subsequently separated certain business assets and licensed certain molecular-diagnostics technology to a newly formed entity, Decisive Diagnostics. By October 2011, Joseph Sorge, identified as Stratagene’s original founder and chief executive, was serving as chief executive of Decisive Diagnostics. The available material therefore treats Stratagene California as a former independent company whose technology and activities continued in part through Agilent and the new diagnostics entity rather than as an active standalone brand.

Stratagene California was founded in 1984 and incorporated in California, becoming one of the biotechnology companies associated with the development of commercial laboratory tools for molecular and cellular research. It was headquartered in La Jolla, a major Southern California life-science center. The company’s work covered a broad set of applications, including cellular analysis, cloning, cytogenomics, DNA methylation, DNA sizing and quantification, food testing, and molecular diagnostics. During its early development, Stratagene operated in a market shaped by the growing use of recombinant DNA methods, genomic analysis, and specialized laboratory assays. Its commercial role was to provide research and testing technologies that helped professional users analyze biological samples, manipulate DNA, and perform measurements relevant to research and diagnostic workflows. The available sources do not provide a complete chronology of individual product launches, but they indicate that the company competed through specialized biotechnology capabilities and intellectual property. The company received attention for its entrepreneurial development during the 1980s. A 1987 Los Angeles Times item reported that two people from Stratagene received Entrepreneur of the Year recognition. In the early 1990s, the company was involved in a federal-court technology dispute described by the San Diego Union-Tribune as a battle over “silver bullet” technology. A 1991 report also discussed plans for a partial move, suggesting that Stratagene was managing physical expansion or organizational changes as its business developed. Stratagene broadened its corporate platform in 2004 through the acquisition of Hycor. Contemporary reporting also described the company as going public that year. This expansion occurred as biotechnology-tool companies increasingly sought applications beyond basic research, including clinical, diagnostic, and testing markets. Stratagene’s stated areas of activity included food testing and molecular diagnostics alongside its established research-tool businesses. Intellectual property remained an important issue during the company’s later independent period. In 2005, reporting concerning litigation involving Third Wave Technologies described a court award of $15.9 million after damages were tripled. The available materials identify the dispute and its reported damages but do not provide enough information to characterize every claim, appeal, or final settlement detail. In 2007, Agilent Technologies acquired Stratagene for approximately $250 million. The acquisition absorbed Stratagene into Agilent and ended its status as an independent company. Agilent spun off certain assets and licensed selected molecular-diagnostics technology to Decisive Diagnostics. By October 2011, Joseph Sorge, described as Stratagene’s original founder and chief executive, was leading Decisive Diagnostics. Stratagene California is therefore best understood as a former biotechnology corporate brand whose research and diagnostic capabilities were partly integrated into a larger technology company and partly continued through a successor diagnostics venture.

• 2011

  Joseph Sorge led Decisive Diagnostics

  [1]Stratagene Californiaen.wikipedia.org

  By October 2011, Stratagene founder Joseph Sorge was identified as chief executive of Decisive Diagnostics, the entity receiving selected diagnostics assets and technology.

• 2007

  Agilent Technologies acquired Stratagene

  [1]Stratagene Californiaen.wikipedia.org

  Agilent acquired Stratagene for approximately $250 million, ending its independent operation.

• 2005

  Patent litigation damages were reported

  [1]Stratagene Californiaen.wikipedia.org

  A report on litigation involving Third Wave Technologies stated that damages were increased to $15.9 million.

• 2004

  Hycor acquisition and public-market expansion

  [1]Stratagene Californiaen.wikipedia.org

  Stratagene acquired Hycor and was reported to have gone public, broadening its corporate and commercial platform.

• 1991

  Partial relocation plans were reported

  [1]Stratagene Californiaen.wikipedia.org

  The San Diego Union-Tribune reported that the biotechnology company planned a partial move.

• 1987

  Company executives received entrepreneurial recognition

  [1]Stratagene Californiaen.wikipedia.org

  Contemporary reporting stated that two people from Stratagene received Entrepreneur of the Year awards.

• 1984

  Stratagene was established

  [1]Stratagene Californiaen.wikipedia.org

  Stratagene was established and incorporated in California as a biotechnology company serving life-science research and diagnostic applications.

A specialized biotechnology and life-science tools provider focused on molecular biology research, cellular and genomic analysis, diagnostics, and related testing applications.

• Life-science research products

  Molecular biology research tools

  Stratagene developed laboratory technologies for molecular biology research, supporting workflows involving DNA analysis, cloning, measurement, and related experimental procedures. The available reference material identifies this as a core area but does not supply a complete historical product catalog.

• Cell biology tools

  Cellular analysis technologies

  The company participated in cellular-analysis applications, providing tools or technologies intended for professional investigation of cellular characteristics and biological processes. Specific product names and launch dates are not provided in the available sources.

• Molecular and genomic research

  Cloning and genomic analysis tools

  Stratagene’s stated fields included cloning and cytogenomics. These activities placed the company within the market for laboratory methods used to manipulate, examine, and interpret genetic material.

• DNA analysis

  DNA methylation, sizing, and quantification technologies

  The company worked on DNA methylation as well as DNA sizing and quantification, areas relevant to molecular research, quality control, and diagnostic development. The references do not identify individual kits, instruments, or assay families.

• Diagnostics and testing

  Molecular diagnostics and food-testing technologies

  Stratagene was involved in molecular diagnostics and food testing, extending its technology base into applied detection and testing markets. After the Agilent acquisition, selected molecular-diagnostics technology was licensed to Decisive Diagnostics.

• 2007

  Sale to Agilent TechnologiesM&A

  Background

  Stratagene had developed a portfolio spanning research tools, diagnostics, and testing technologies.

  Action taken

  Agilent Technologies acquired Stratagene for approximately $250 million.

  Aftermath

  Stratagene ceased operating as an independent company. Certain assets were spun off, while selected molecular-diagnostics technology was licensed to Decisive Diagnostics.

  Reported acquisition value. $250 million (2007 acquisition)

  Source

• 2004

  Acquisition of HycorM&A

  Background

  Stratagene was seeking broader commercial reach across biotechnology and diagnostic applications.

  Action taken

  The company acquired Hycor and was also reported to have entered public markets.

  Aftermath

  The transaction expanded Stratagene’s corporate platform before its later sale to Agilent Technologies.

  Source

• 2007

  Agilent Technologies acquired Stratagene[1]Stratagene Californiaen.wikipedia.org

  M&A

  Agilent Technologies acquired Stratagene in a transaction reported at approximately $250 million, ending Stratagene’s existence as an independent biotechnology company.

• 2007

  Stratagene assets and molecular-diagnostics technology were separated after the acquisition[1]Stratagene Californiaen.wikipedia.org

  M&A

  Following the Agilent transaction, certain business assets were spun off and selected molecular-diagnostics technology was licensed to Decisive Diagnostics.

• 2005

  Patent dispute involving Third Wave Technologies[1]Stratagene Californiaen.wikipedia.org

  Lawsuit · Other

  Contemporary reporting described a patent-infringement case involving Third Wave Technologies in which damages were increased to $15.9 million. The available reference does not fully establish the parties’ procedural roles or the final legal outcome for Stratagene.

• 2004

  Stratagene acquired Hycor and went public[1]Stratagene Californiaen.wikipedia.org

  M&A · Other

  Contemporary reporting described Stratagene’s acquisition of Hycor and its move into public-company status, reflecting an expansion of its business platform.

1. 1Stratagene Californiaen.wikipedia.org